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BACKGROUND: Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab,
a chimeric, murine-human mAb against IL-6, was evaluated in a three-part phase I/II study in patients with progressive metastatic RCC.
METHODS:I np a r t1 ,1 1p a t i e n t sr e c e i v e d1 ,3 ,6 ,o r1 2m gk g
–1at weeks 1, 4 and q2w  2 thereafter; in part 2, 37 patients randomly
received 3 or 6mgkg
–1q3w  4; in part 3, 20 low-risk patients received 6mgkg
–1q2w  6. Modified WHO response criteria were
assessed at weeks 7, 11, the 6-week follow-up, and when clinically indicated.
RESULTS: Siltuximab was well tolerated overall, with no maximum tolerated dose or immune response observed. In all, 5 out of 11,
17 out of 37, and 9 out of 20 patients in parts 1, 2, and 3, respectively, received extended treatment beyond 4–6 initial infusions. In part
2, stable disease (SD) (X11weeks) or better was achieved by 11 out of 17 (65%) 3mgkg
–1treated patients (one partial response (PR)
B8 months, 10 SD) and 10 out of 20 (50%) 6mgkg
–1 treated patients (10 SD). In part 3, documented complete or PR was not
observed, but 13 out of 20 (65%) patients achieved SD.
CONCLUSION: Siltuximab stabilised disease in 450% of progressive metastatic RCC patients. One PR was observed. Given the favourable
safety profile of siltuximab and poor correlation of tumour shrinkage with clinical benefit demonstrated for other non-cytotoxic
therapies, further evaluation of dose-escalation strategies and/or combination therapy may be considered for patients with RCC.
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The inflammatory cytokine interleukin (IL)-6, is part of an
autocrine cytokine network that influences tumour growth. The
production of cancer-related factors supporting IL-6 production
by the tumour correlate with its propensity to establish distant
metastases. In particular, metastatic renal cell carcinoma (RCC) is
frequently associated with elevated levels of IL-6, which have been
reported to correlate with metastatic progression, poor prognosis,
shorter survival (Blay et al, 1992; Negrier et al, 2004), as well as
poor response (Fumagalli et al, 1999) and high toxicity (Capuron
et al, 2001) to IL-2 therapy.
An estimated 30–40% of RCC cases eventually advance to
metastatic disease (Glaspy, 2002). This is often accompanied by
paraneoplastic syndrome, a condition characterised by fever,
elevated levels of acute phase markers such as C-reactive protein
(CRP), a decrease in serum albumin, anaemia, and thrombo-
cytosis, all of which appear to be because of abnormal cytokine
production, in particular IL-6, or immunogenic mechanisms (Blay
et al, 1997; Altundag et al, 2005). Until recently, cytokines
(IL-2 and interferon-a (IFNa)) were the only drugs shown to
induce tumour regression in patients with metastatic RCC. Today,
prolongation of the time to progression in patients with RCC has
been demonstrated for the tyrosine kinase inhibitors sorafenib
(Escudier et al, 2007a), sunitinib (Motzer et al, 2007), as well as
temsirolimus (Hudes et al, 2007) and bevacizumab (Escudier et al,
2007b). However, these agents are associated with significant
adverse effects, and the need for curative therapy remains.
Monoclonal antibodies against IL-6 have been studied for more
than one decade. BE-8 (Diaclone, Besanc¸on, France), a fully
murine monoclonal antibody against IL-6, inhibited RCC- and IL-
2/IFNa-associated toxicities in preliminary reports of testing in
patients with metastatic RCC (Rossi et al, 1992; Blay et al, 1997).
However, human anti-murine antibodies to BE-8 were detected
(Legouffe et al, 1994), and daily production of IL-6 levels
418mgday
–1 could not be efficiently blocked with the doses of
BE-8 tested (Lu et al, 1995). Thus, further exploration of chimeric
or fully human anti-IL-6 antibodies was warranted.
Siltuximab (formerly known as CNTO 328) is a chimeric,
murine-human monoclonal antibody that binds with high affinity
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sand specificity to IL-6 (van Zaanen et al, 1996). Preclinical
experience has shown that siltuximab inhibits the growth of
human RCC tumours and decreases serum calcium concentrations
in nude mice (Weissglas et al, 1995). An earlier formulation of
siltuximab was evaluated in a phase I, dose-ranging study of 10, 20,
or 40mg daily infusions administered in two 2-week cycles to 12
patients with multiple myeloma. This study demonstrated
biological activity (van Zaanen et al, 1998). Eight of nine patients
with detectable CRP concentrations showed a reduction to a level
below detection, and all nine patients showed suppression of
circulating free IL-6 60 days post-treatment. The antibody was well
tolerated, and no immune responses to siltuximab were observed.
These results were encouraging and supported further evaluation
of the antibody in less frequent and longer-term dosing.
In this paper, we present the clinical data from the first-in-
human, phase I/II study of this formulation of siltuximab in
continuous dosing, conducted in patients with metastatic RCC.
The objectives of this study were to evaluate the safety,
pharmacokinetics, and preliminary efficacy of siltuximab in the
treatment of patients with metastatic RCC and to determine the
recommended dose for further studies. In-depth pharmacokinetic
and pharmacodynamic results of the study have been published
separately (Puchalski et al, 2010).
MATERIALS AND METHODS
Study design
This study was conducted in three parts. Part 1 was a phase I,
open-label dose-escalation study to assess safety and single-dose
pharmacokinetics of siltuximab at three dose levels (1, 3, and
6mgkg
–1 on days 1, 29, 43, and 57) and to determine the two
highest safe doses for further evaluation in part 2. The starting
dosage regimen for part 1 of this phase I/II study was selected in an
attempt to sufficiently neutralise the circulating level and
endogenous production of IL-6. Maximum suppression of CRP
concentrations to below the lower limit of quantification (LLOQ)
throughout the dosing interval was anticipated to provide the best
opportunity for CNTO 328 therapy to demonstrate clinical activity
(Puchalski et al, 2010).
Enrolment was initiated with the lowest dose cohort and only
proceeded to the next dose level after the Safety Monitoring
Committee (SMC) reviewed safety data and recommended dose
escalation.
On recommendation of the SMC, the protocol was later
amended to explore a fourth dose, 12mgkg
–1, in patients with
high (X50mgl
–1) baseline serum CRP at one centre only. The
enrolment of this cohort coincided with the enrolment for part 2
and was not considered for dose selection.
Part 2 was a proof-of-concept, phase II, randomised, double-
blind, Simon 2-stage design to evaluate two safe siltuximab dose
levels from part 1 (3 and 6mgkg
–1administered 1:1 q3w for four
cycles). As both treatment cohorts met the effective dose criterion
in stage 1, the independent Safety and Efficacy Monitoring
Committee decided not to proceed to stage 2 of part 1. An open-
label part 3 was added to further evaluate 6mgkg
–1siltuximab at a
more frequent dosage regimen (q2w for six cycles) that would
most likely completely neutralise circulating free IL-6 (as indicated
by CRP suppression) in a more select patient population (i.e., low
risk with Motzer score p1 and CRP levels o30mgl
–1).
For all study parts, patients demonstrating at least stable disease
(SD) could receive extended administrations of siltuximab at the
assigned dose (q3w for p4 total infusions (part 1), or q3w (part 2)
or q2w (part 3) for up to p6 infusions). The study agent was
stopped for any patient with disease progression. After the last
siltuximab infusion, patients were followed for 24 weeks for
pharmacokinetics, pharmacodynamics, and immune response
evaluations; and every 2 months for up to 1 year for disease
status, post-study treatments, and survival.
Patient population
Patient eligibility criteria were: age X18 years, clinically diagnosed
metastatic RCC with documented metastases beyond the regional
lymphatics (any T, any N, M1 disease); detectable CRP serum
concentrations X4mgl
–1 (and o30mgl
–1 for part 3); measurable
disease (and/or evaluable disease for part 1); documented disease
progression based on objective tumour assessments from two
computed tomography scans within 6 months before enrolment;
Karnofsky performance status X60; Motzer score (Motzer et al, 2004)
p1( p a r t3o n l y ) ;X4 weeks wash-out since previous systemic cancer
therapy, radiotherapy, or surgery;a d e q u a t eb o n em a r r o w ,l i v e r ,a n d
renal function (haemoglobin X9g per 100ml, white blood cells
X3.5 10
9l
–1, neutrophils X1.5 10
9l
–1, platelets X100 10
9l
–1,
serum creatinine p2mg per 100ml, liver function tests p2  upper
limit of normal (ULN) if no liver metastasis or p5  ULN if liver
metastasis); active birth control for women of child-bearing potential;
and life expectancy X6m o n t h s .
Exclusion criteria were the use of any investigational drug within
30 days or five half-lives; any history of receiving murine/chimeric
proteins or human/murine recombination products; serious con-
current illness or significant cardiac disease characterised by
significant ischaemic coronary disease or congestive heart failure;
chronic, recurrent, or clinically important active infection; solid
organ transplant (except corneal 43 months before screening),
allogeneic bone marrow transplant, or peripheral blood stem cell
transplant; central nervous system metastatic disease; previous non-
RCC malignancy except adequately treated basal/squamous cell skin
carcinoma, cervical cancer, or other cancer in remission for X5
years; other concurrent immunotherapy, biotherapy, chemotherapy,
investigative therapy, radiotherapy, or immunosuppressive therapy;
planned concomitant nephrectomy; pregnant or lactating; known
HIV, hepatitis B or C; autoimmune disease; or any medical condition
that in the investigator’s opinion might compromise patient
adherence to the study agent.
The protocol was approved by the independent ethics committee
at each site. All patients provided written informed consent.
Study assessments
Safety Primary safety assessments included the monitoring of
siltuximab-related dose-limiting toxicity (DLT) according to the
National Cancer Institute Common Toxicity Criteria Version 2.0,
Bethesda, MD, USA; adverse events (AEs); serious adverse events
(SAEs); and clinically significant changes from baseline in vital
signs, safety-related laboratory parameters, and abnormal electro-
cardiograms.
In part 1, a 48-h safety assessment was performed after the first
administration to the first patient in each cohort before additional
patients could be enrolled. If no DLT (any grade X3 toxicity
identified by the SMC as dose limiting) was observed, the doses
were considered safe and no maximum tolerated dose (MTD) was
reached. If a DLT was observed at a lower dose level after
escalation, the SMC would make a recommendation on which dose
level, if any, to continue to study.
Pharmacology Blood samples to determine pharmacokinetics
and pharmacodynamics of CNTO 328 were obtained from all
patients within 2 weeks before the first infusion and during and in
between each infusion visit for analysis. Although CRP is not a
validated biomarker in RCC patients, we believe CRP suppression
is a meaningful surrogate marker for demonstrating inhibition of
IL-6 signaling. Serum amyloid A (SAA), also induced by IL-6 as an
acute-phase inflammatory protein, and soluble IL-6 receptor
(GP80, sIL-6R) and GP130 were investigated as other potential
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these biomarkers are possibly more sensitive than CRP to IL-6
changes. Increased GP130 serum concentrations are associated
with increased IL-6 in rheumatoid arthritis (Tanaka et al, 2000). As
IL-6 affects bone resorption, which is generally associated with
increased circulating serum C-telopeptide (CTx) and N-telopeptide
(NTx) levels of collagen, additional pharmacodynamic data on
serum NTx and CTx were measured by ELISA.
Detailed results on siltuximab pharmacokinetics and the serum
concentrations of the pharmacodynamic markers CRP, SAA, and
IL-6 are presented separately in the pharmacokinetic/pharmaco-
dynamic modeling paper, because the assessment of CRP
suppression was used to determine the optimal dose levels of
siltuximab and SAA was positively correlated with CRP and
therefore was considered a good alternative biomarker of
siltuximab treatment (Puchalski et al, 2010). Data on soluble
GP130, NTx, and CTx are presented here.
Additional blood samples were collected from all patients
immediately before the first infusion and at 6, 12, 18, and 24
weeks after the last infusion to evaluate the presence of antibodies
to siltuximab, that is, any increase from baseline in anti-siltuximab
antibody titre in which the increased reactivity demonstrated
specific binding to siltuximab.
Efficacy Overall tumour response was assessed using modified
World Health Organisation (WHO) criteria through pertinent
radiologic examination (excluding ultrasound) of bidimensionally
measurable lesions. Complete response (CR) and partial response
(PR) required confirmation by repeat radiologic assessment X4
weeks later. In part 1, the assessments were performed at baseline,
week 9, and at the 6-week follow-up. For parts 2 and 3, radio-
logic assessments were performed at baseline, week 7, week 11
(to confirm a potential response), when clinically indicated, and
6 weeks after the last siltuximab administration. The same
radiological method was to be used during all timepoints.
The primary efficacy endpoint was the proportion of patients with
a best response of CR, PR, or SD for parts 1 and 2 and of CR or PR
for part 3, both within 11 weeks after the first siltuximab
administration. A more stringent endpoint was chosen for part 3
because better response was expected in the highly selected patients.
Major secondary endpoints included the time to progressive
disease (PD), the proportion of patients with CR or PR, the duration
of CR or PR, and the proportion of patients with clinical benefit. For
this study, clinical benefit response was defined as improvement in
X1 and stable condition for the remaining criteria as follows: X2-
unit improvement in worst pain measurement according to question
3 of the Brief Pain Inventory short form, X10% absolute
improvement from baseline in Karnofsky performance status,
X10% increase from baseline in body weight. This definition of
clinical benefit response has not been formally validated.
The functional assessment of chronic illness therapy – fatigue
questionnaire was also administered.
Statistical analyses
Summary statistics were provided for continuous data, and rates
and percentages for categorical data. Kaplan–Meier survival
analyses were performed for time-to-event data. Baseline was
defined as the last measurement before the first siltuximab
administration. Formal hypothesis testing was performed only
for the primary efficacy endpoints in parts 2 and 3. All statistical
analyses were performed by BioCor using SAS Version 8.2 (SAS
Institute Inc., Cary, NC, USA).
For part 1, a sample size of 3–21 patients was planned to allow
for cohort expansion in the event of a DLT. For part 2, according to
optimal Simon 2-stage design, the planned sample size of X18
patients per group for stage 1 and an additional 25 patients for
stage 2 was calculated based on the null hypothesis that o10% of
patients would achieve response (CR, PR, unconfirmed CR or PR,
or SD) and the alternative hypothesis that X25% would achieve
response at an a-level of 0.05 and b-level of 0.20. Under these
assumptions, the study would proceed to stage 2 if 42 patients in
a dose cohort achieved response. A dose was effective if 47
patients overall (stages 1 and 2) in that dose cohort achieved
response. For part 3, the planned sample size of 20 patients was
calculated based on the null hypothesis that o5% of patients
would achieve response (CR or PR) and the alternative hypothesis
that X25% would achieve response at an a-level of 0.10 and b-level
of 0.10. Under these assumptions, siltuximab would be considered
effective if X3 patients achieved response in part 3.
RESULTS
A total of 68 patients were enrolled from June 2003 to May 2006
across parts 1 through 3 at multiple European sites. Baseline
demographics and disease characteristics were well balanced
across the study parts (Table 1).
Eleven patients were enrolled in part 1: one patient received
1mgkg
–1, three patients each received 3 or 6mgkg
–1, and four
patients received 12mgkg
–1. In all, 9 of these 11 patients had
unilateral nephrectomy for RCC, and 4 had received radiotherapy
for metastatic disease. Seven patients had been treated with IFNa
and four with the combination of IFNa and IL-2. The highest
number of previous cancer-related systemic therapies used was
three (in two patients), and the best response to the last systemic
therapy was SD (n¼4). Of these 11 patients, 8 received all 4
planned study-agent infusions, including 5 who went on to receive
extended treatment (4 received 4 extended infusions and 1
received 1 extended infusion). The median time from the first to
the final study-agent administration for the treatment cohorts
combined was 57 days (range 1–64 days).
A total of 38 patients were randomised in part 2: 18 patients to
3mgkg
–1 and 20 patients to 6mgkg
–1, although one patient
assigned to 3mgkg
–1did not meet entry criteria and consequently
did not receive any study agent (Figure 1). All but three patients
had previous surgery for RCC. In all, 30 patients had previous
cancer-related systemic therapy, 22 of whom had p2 regimens.
Among patients who had 42 regimens, six patients had received
three regimens, one patient had received four regimens, and
one patient in the 3mgkg
–1 dose group had received nine
regimens. The most commonly used systemic therapy was
cytokine-based (e.g., IFNa, IL-2), whereas fewer patients had
received chemotherapy or hormonal therapies; the best response
achieved was PR for four patients in the 3mgkg
–1 group. More
patients had previous radiation therapy in the 6mgkg
–1 group
than in the 3mgkg
–1 group (8 vs 1, respectively). Among the 37
treated patients, 23 received all four planned infusions, including
17 who went on to receive at least one extended treatment
(one patient with PR received the maximum of six extended
treatments over 18 weeks). The median time from the first to the
final administration for the treatment groups combined was 71
days (range 22–233 days).
In part 3, 20 patients (at baseline 12 had a Motzer score of 0
and 8 had a score of 1) received 6mgkg
–1siltuximab. All patients
had unilateral nephrectomy, and one had received radiotherapy.
In total, 18 patients had received cancer-related systemic therapy;
16 patients had been treated with IFNa, among whom 10 had
received a combination of IFNa and an IL. Only one patient
received 42 regimens. The best responses achieved with the
last systemic therapy were CR (n¼1) and PR (n¼3). Among these
20 patients, 13 received all 6 planned infusions, including 9
who went on to receive at least one extended treatment (one
patient received 7 extended treatments over 14 weeks). The median
time from the first to the final administration was 71 days
(range 1–239 days).
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Siltuximab was well tolerated and demonstrated a consistent safety
profile across all cohorts and each study part. Administration of
6mgkg
–1 q3w in part 2 and q2w in part 3 did not result in
significantly different safety profiles. No DLT, dose-related
toxicity, or dose response for any specific AE or system-class AE
was observed. No MTD was established.
Almost all treated patients (66 of 68) in parts 1 through 3 had
X1 AE (Table 2). The majority of individual AEs were not reported
by more than one patient each. Reasonably related AEs were
reported in 46 patients; fatigue (n¼9) and dizziness (n¼5) were
most frequently reported. Twenty-seven (40%) patients had X1
AE of toxicity grade X3. In part 1, all grade X3 AEs were reported
by only one patient each, and none were considered likely related
to the study agent. In part 2, the majority of grade X3 AEs were
reported by only one patient per treatment group; the most
frequently reported were fatigue, chest pain, back pain, dyspnoea,
and hypertension (each n¼2). In part 3, four patients had one or
more grade X3 AEs (transaminases increased, syncope, pain,
musculoskeletal pain, and hypercalcaemia (each n¼1)). Of the
reasonably related AEs reported, eight were grade X3 in part 2
18 randomly assigned to 3 mg kg–1 q3w 20 randomly assigned to 6 mg kg–1 q3w
17 received 3 mg kg–1 q3w 
1 discontinued study 20 received 6 mg kg–1 q3w
6 discontinued siltuximab through week 9
5 disease progression
0 adverse event
1 other
9 discontinued siltuximab through week 9
8 disease progression
1 adverse event
0 other
4 discontinued siltuximab through week 15
3 disease progression
0 death
1 other
4 discontinued siltuximab through week 15
2 disease progression
2 death
0 other
9 received extended 6 mg kg–1 q3w 8 received extended 3 mg kg–1 q3w
17 patients analysed 20 patients analysed
38 patients
Figure 1 CONSORT diagram for the randomised part 2.
Table 1 Baseline demographics and disease characteristics
Part 1 Dose escalation
Part 2 Dose finding Part 3 Dose
confirmation
Dosage 1, 3, 6, or 12mgkg
 1 on days 1, 29, 43, 57
3mgkg
 1
q3w
6mgkg
 1
q3w Total 6mgkg
 1 q2w
Patients enrolled 11 18 20 38 20
Patients treated 11 17 20 37 20
Male 9 (82) 9/18 (50) 17 (85) 26 (68) 19 (95)
Caucasian 11 (100) 17/17 (100) 20 (100) 37 (100) 19 (95)
Age 60 (56, 73) 57 (39, 72) 57 (26, 82) 57 (26, 82) 62 (50, 77)
Site of primary diagnosis
Right 4 (36) 8/17 (47) 12 (60) 20 (54) 13 (65)
Left 6 (55) 6/17 (35) 8 (40) 14 (38) 7 (35)
Bilateral 1 (9) 3/17 (18) 0 3 (8) 0
Tumour histology
N 10 16 19 35 20
Clear cell 9 (90) 16 (100) 17 (90) 33 (94) 18 (90)
Papillary 0 0 1 (5) 1 (3) 1 (5)
Other 1 (10) 0 1 (5) 1 (3) 1 (5)
Patients with previous systemic cancer therapy 7 (64) 14/17 (82) 16 (80) 30 (81) 18 (90)
Patients with previous radiation therapy 4 (36) 1/17 (6) 8 (40) 9 (24) 1 (5)
Patients with RCC-related surgery 9 (82) 16/18 (89) 19 (95) 35 (92) 20 (100)
Abbreviation: RCC¼renal cell carcinoma. Data presented as n (%) or median (range).
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cough, and upper abdominal pain (each n¼1)) and two were
grade X3 in part 3 (pain and syncope (each n¼1)).
Serious AEs were reported in 5 (46%) patients in part 1, 12
(32%) in part 2, and 3 (15%) in part 3. One patient in part 2 who
received three infusions of 6mgkg
–1siltuximab suffered a grade 4
SAE of cardiac failure on day 78 and consequently withdrew from
study participation. This was the only SAE considered possibly
related to siltuximab, although the investigator reported inflow
obstruction by the large tumour masses in the mediastinum as the
most likely cause of cardiac failure. A total of five patients died
during the study: four patients died from disease progression: two
12mgkg
–1treated patients in part 1 (on days 31 and 106) and two
6mgkg
–1 treated patients in part 2 (on days 45 and 66). One
6mgkg
–1 treated patient died from a grade 4 SAE of massive
cerebral haemorrhage secondary to metastatic disease in part 3
(on day 107).
No anaphylactic or delayed hypersensitivity reaction was
observed. Among the 10 patients who reported possible infusion
reactions (Table 2), none required an interruption of the infusion
or a discontinuation of subsequent infusions. No treatment-related
changes in vital signs (except for increased blood pressure in
part 2), electrocardiogram, urinalysis, or clinical chemistry para-
meters were evident. In parts 2 and 3, trends toward decreases
from baseline in the haematology parameters platelets, white blood
cells, and neutrophils were observed with prolonged study-agent
administration; all three parameters trended toward recovery upon
study-agent discontinuation.
Pharmacology Using a stepwise design, pharmacokinetic/phar-
macodynamic modeling was used in which a target trough
siltuximab serum concentration of 21mgml
–1 was predicted to
be effective in maintaining complete CRP suppression throughout
the dosing interval (Puchalski et al, 2010). In parts 1 and 2,
although a decrease from baseline in CRP was evident in both the 3
and6mgkg
–1 cohorts, CRP was inadequately suppressed in both
cohorts when a patient’s baseline serum CRP was 430mgl
–1.
Total CRP suppression was also not achieved in the 12mgkg
–1
dose cohort in which patients had the highest baseline CRP
concentrations (CRP 450mgl
–1). The pharmacokinetic/pharma-
codynamic modeling simulation showed that dosing at 6mgkg
–1
q2w or 9mgkg
–1 q3w would suppress CRP to below the LLOQ
throughout siltuximab treatment (Puchalski et al, 2010). In part 3,
administration of siltuximab 6mgkg
–1 q2w appeared to suppress
CRP in all 20 patients with baseline CRP serum concentrations
o30mgl
–1.
Briefly summarised from Puchalski et al, (2010), SAA concen-
trations were variable in part 1 and remained low throughout the
treatment period in parts 2 and 3; total and free IL-6 serum
concentrations gradually increased in parts 1 and 2, and was not
measured in part 3. Levels of soluble IL-6R (GP80) and soluble
GP130 both increased from baseline for the 3 and 6mgkg
–1
cohorts following siltuximab administration in parts 2 and 3. The
increase in soluble IL-6R was greater in the 6-mgkg
–1than in the
3mgkg
–1dose cohort in part 2. In part 2, patients in the 6mgkg
–1
dose cohort generally had higher levels of serum NTx and CTx
than those in the 3mgkg
–1dose cohort, and both serum NTx and
CTx varied considerably without showing any specific trend. In
part 3, an increase in serum levels of both NTx and CTx was
evident following the initial siltuximab administrations; both
decreased to below baseline levels by the end of the study.
Among the 44 of 68 patients in parts 1 through 3 with one or
more samples obtained after the first siltuximab administration,
none were positive for antibodies against siltuximab at any time.
Table 2 Summary of study-agent exposure and safety, treated patients
Part 1 Dose escalation
Part 2 Dose finding Part 3 Dose
confirmation
Dosage 1, 3, 6, or 12mgkg
–1on days 1, 29, 43, 57
3mgkg
–1
q3w
6mgkg
–1
q3w Total 6mgkg
–1q2w
Patients treated 11 17 20 37
a 20
Patients treated with extended
administrations
5 (45) 8 (47) 9 (45) 17 (46) 9 (45)
Doses received 4 (1, 8) 4 (2, 10) 4 (2, 8) 4 (2, 10) 6 (1, 13)
Days from first to final administration 57 (1, 64) 78 (29, 233) 64 (22, 212) 71 (22, 233) 71 (1, 239)
Patients who discontinued study agent 3 (27) 6 (35) 9 (45) 15 (41) 7 (35)
Primary reason
Disease progression 1 (9) 5 (29) 8 (40) 13 (35) 4 (20)
Adverse event 1 (9)
b 0 1 (5)
c 1 (3) 1 (5)
d
Other 1 (9)
e 1 (6)
f 0 1 (3) 2 (10)
f,g
Patients who terminated study participation 3 (27) 4 (24) 4 (20) 8 (22) 3 (15)
Primary reason
Disease progression 1 (9) 3 (17) 2 (10) 5 (14) 0
Death 0 0 2 (10) 2 (5) 1 (5)
Other 2 (18)
e,f 1 (6)
f 0 1 (3) 2 (10)
g
Duration of follow-up, mean (days) 76 65 72 68 141
Patients with X1 adverse events 11 (100) 17 (100) 19 (95) 36 (97) 19 (95)
Reasonably related 6 (55) 12 (71) 13 (65) 25 (68) 15 (75)
Grade 3 or higher 6 (55) 7 (41) 10 (50) 17 (46) 4 (20)
Patients with X1 possible infusion reactions 1 (9) 2 (12) 4 (20) 6 (16) 3 (15)
Patients with X1 serious adverse events
h 5 (46) 4 (24) 8 (40) 12 (32) 3 (15)
Reasonably related 0 0 1 (5) 1 (3) 0
Death 2 (18) 0 2 (10) 2 (5) 1 (5)
aOne patient assigned to 3mgkg
–1did not meet entry criteria and consequently did not receive the study agent.
bPneumonia.
cCardiac failure.
dProteinuria.
eSponsor initiated.
fOne patient withdrew consent.
gOne patient with a history of renal failure and elevated hypertension had a recurrence of both.
hThe following serious adverse events were
reported: back pain, vomiting, arthralgia, peripheral motor neuropathy, anaemia, dyspnoea, pleural effusion, confusional state, general health deterioration, acute respiratory
distress syndrome, bone pain, cardiac failure, acute pancreatitis, chest pain, sepsis, upper limb fracture, increased blood creatinine, cancer pain, spinal cord compression, vulval
oedema, cerebral haemorrhage, upper abdominal pain, and leg ache. Data presented as n (%) or median (range) unless specified otherwise.
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In part 1, five patients had an overall response of SD (3mgkg
–1,
n¼1;6mgkg
–1, n¼3; 12mgkg
–1, n¼1). In part 2, the primary
endpoint of CR, PR, or SD was achieved: one patient had PR and 20
(10 each in the 3 and 6mgkg
–1cohorts) had SD (Table 3), that is,
both cohorts met the effective dose criterion in stage 1. The patient
with PR had neck and pancreatic metastases that had progressed
despite treatment with high-dose IL-2, IFNa, and 5-fluorouracil 2
months before receiving 3mgkg
–1 siltuximab. Partial response
was observed in the target neck lesion during the first radiologic
assessment at week 7 and was sustained for 228 days before
radiologic examination on day 283 showed PD. This patient
received 10 total infusions (4 scheduled plus 6 extended). Her CRP
serum concentration decreased from a baseline concentration of
36mgl
–1to below 10mgl
–1and remained suppressed throughout
her treatment. Overall, the median time to PD for all treated
patients was 102 (95% CI: 52, 169) days. The time to PD for the
patients with SD ranged from 78 to 254 days (Figure 2A). A higher
proportion of patients who responded to treatment with siltux-
imab had low baseline CRP (o30mgl
–1) compared with those
who had high baseline CRP (46 vs 11%). For patients with a CRP
serum concentration below the LLOQ at the third infusion, 14
(74%) of 19 had a best response of SD. No patient with a baseline
CRP X100mgl
–1 had a response of SD or better.
In part 3, the primary endpoint of CR or PR was not achieved,
although 13 of 20 patients demonstrated SD (Table 3). The median
time to PD for all treated patients was 80 (95% CI: 50, 130) days.
For the 13 patients with SD, the time to PD ranged from 78 to 176
days (Figure 2B). Of these patients, four were right-censored
because they had no reported PD during the study.
The maximum percentage of tumour reduction from baseline is
shown for parts 2 and 3 combined in Figure 3. There was no
significant difference in tumour reduction from baseline between
patients treated with siltuximab administered at 3mgkg
–1 q2w,
6mgkg
–1 q2w, and 6mgkg
–1 q3w.
In part 1, 5 of 10 patients at week 4 (1mgkg
–1, n¼1; 3mgkg
–1,
n¼1, 6mgkg
–1, n¼1; 12mgkg
–1, n¼2), 3 of 9 at week 6
(6mgkg
–1, n¼1; 12mgkg
–1, n¼2), and 2 of 8 at week 8
(6mgkg
–1, n¼1, 12mgkg
–1, n¼1) were clinical benefit respon-
ders. An early small improvement (B20%) in clinical benefit
response was observed in both parts 2 and 3, although this was
difficult to evaluate because of a lack of adequate data beyond 6
weeks. An improvement in fatigue was seen for B35% of patients
up to week 6 in part 2; this benefit was not seen in part 3, likely
because of the low level of fatigue in this population at baseline.
Table 3 Summary of efficacy outcomes
Part 2 Dose finding
Part 3 Dose confirmation
Dosage 3mgkg
 1 q3w 6mgkg
 1 q3w Total 6mgkg
 1 q2w
Patients treated 17 20 37 20
Responders 11 (65) 10 (50) 21 (57) 13 (65)
Complete response 0 0 0 0
Partial response 1 (6) 0 1 (3) 0
Stable disease 10 (59) 10 (50) 20 (54) 13 (65)
Nonresponders 6 (35) 10 (50) 16 (43) 7 (35)
Progressive disease 6 (35) 10 (50) 16 (43) 7 (35)
Patients who received extended infusions 8 (47) 9 (45) 17 (46) 9 (45)
Duration of overall response (CR + PR), days
N 10 1 0
Median 228 — 228 —
Time to tumour progression (PD), days
Median (95% CI) 104 (60, 210) 66 (50, 189) 102 (52, 169) 80 (50, 130)
Observed 15 (88) 18 (90) 33 (89) 16 (80)
Censored 2 (12) 2 (10) 4 (11) 4 (20)
Abbreviations: CI¼confidence interval; CR¼complete response; PD¼progressive disease; PR¼partial response. Data presented as n (%) unless specified otherwise.
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Figure 2 Kaplan–Meier plot of the time to disease progression through
the end of study for treated patients in (A) part 2 and (B) part 3.
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Patients with metastatic RCC may have highly variable presenta-
tion and clinical course, however, our study population had
advanced, refractory, PD. Almost all treated patients had previous
surgery for RCC, the majority had at least one previous systemic
cancer treatment, and all had documented PD before study entry.
In parts 1 and 2, patients’ baseline clinical features and signs and
symptoms profiles were typical of a population with advanced
stage RCC (Atzpodien et al, 2003; Kim et al, 2003; Schips et al,
2003; Cella et al, 2006). Additionally for part 2, retrospective
analysis estimated that one-third of patients had a baseline Motzer
score (Motzer et al, 2004) of 2. For part 3, it was hypothesised that
by selecting low-risk patients (i.e., based on a baseline Motzer
score of p1), this sample population would have a greater
probability of benefiting from an anti-IL-6 antibody. Thus, in part
3, a low-risk population was enrolled (60% of patients had a
Motzer score of 0, 40% of patients had a Motzer score of 1).
Additionally, all patients in part 3 had a CRP serum concentration
of o30mgl
–1.
The majority of patients across all parts of the study had
temporary disease stabilisation with siltuximab and one patient in
the 3mgkg
–1 group of part 2 had a significant tumour response
with a PR. In part 2, the primary endpoint (documented CR, PR, or
SD within 11 weeks after the first siltuximab administration) was
met. Across both parts 2 and 3 of the study, 29% of all evaluable
patients demonstrated some degree of reduction in measurable
disease during the study period. The median time to PD for all
treated patients was 102 (95% CI: 52, 169) days in part 2 and 80
(95% CI: 50, 130) days in part 3. There was a small clinical benefit
response in both parts 2 and 3. A benefit in fatigue was only
observed in part 2, possibly because of the lower fatigue at baseline
observed in the part 3 population. The hypothesis that low-risk
patients have a greater probability of benefit from siltuximab was
not confirmed in part 3.
Interleukin-6 is a biological mediator of CRP production
(Mahmoud and Rivera, 2002). High serum CRP concentrations
have been correlated with elevated IL-6 serum concentrations
(Pelliniemi et al, 1995; Ljungberg et al, 1997) and with poor
prognosis in solid tumours such as colorectal cancer (Chung and
Chang, 2003) and with mortality in RCC (Karakiewicz et al, 2007).
In addition, CRP has a biological role in IL-6 production and
chemoresistance in multiple myeloma (Yang et al, 2007).
On the basis of evidence that CRP can be a biomarker for IL-6
(Pelliniemi et al, 1995; Ljungberg et al, 1997), we hypothesised that
suppression of CRP serum concentration to below the LLOQ of
4mgl
–1 throughout the dosing interval would demonstrate
siltuximab’s clinical activity (Puchalski et al, 2010). In patients
with baseline CRP serum concentrations X30mgl
–1, serum CRP
was inadequately suppressed (or maintained) with siltuximab 3
and 6mgkg
–1 q3w in part 2. Also, a greater percentage of part 2
patients with baseline CRP o30mgl
–1 than with baseline CRP
X30mgl
–1(46 vs 11%) responded to siltuximab treatment. Thus,
an important question that arose during this study was whether
patients with higher serum CRP (i.e., X30mgl
–1) had been given
an insufficient siltuximab dose to suppress their IL-6 levels
adequately to achieve a tumour response.
Interleukin-6 could not be assessed reliably. Other potential
biomarkers of IL-6 inhibition were also examined. Changes in SAA
concentrations were positively correlated with CRP (Puchalski
et al, 2010). The observed dose-dependent increase in GP130
following treatment with siltuximab seemed inconsistent with a
decrease in IL-6 bioactivity as measured by a decrease in CRP
levels, indicating that GP130 cannot be used as a biomarker for
IL-6. Although the overall telopeptide profile for both NTx and
CTx was variable following treatment, there was a hint of altered
bone remodeling with an initial increase in both telopeptides after
treatment, followed by an overall decrease below baseline levels in
part 3. This observation, while consistent with lowered IL-6
bioactivity, is not robust enough to indicate either telopeptide as a
biomarker of anti-IL-6 therapy.
The absence of an MTD further suggested dose escalation as a
possibility for future development. In part 3, the dose regimen was
intensified to 6mgkg
–1 q2w for all patients because the
pharmacokinetic/pharmacodynamic model simulation determined
it would be most effective in maintaining complete suppression of
CRP (Puchalski et al, 2010). Although this regimen suppressed
CRP in all patients, tumour response did not improve in part 3.
The CRP data used for the modeling were not from a high
sensitivity assay. If a high sensitivity CRP assay (i.e., LLOQ of
1mgl
–1) was used, a higher dose of siltuximab might have been
required even in low-risk patients to decrease CRP to below the
more sensitive LLOQ.
On the basis of the modified WHO criteria used in this study,
the rate of CR or PR was low. However, considering the results of
recent pivotal studies with other targeted therapies (Motzer and
Bukowski, 2006; Escudier et al, 2007a) tumour response does not
seem to be a prerequisite for clinical benefit. In reviewing selected
computed tomography scans from one study site, increased
tumour necrosis without significant tumour shrinkage was
detected in two patients. This necrotic effect could have been
because of an anti-angiogenic effect of siltuximab as previously
reported (Zaki et al, 2004). Thus, other strategies for therapy with
siltuximab, including combination with known active agents, can
be considered. Additional measures of clinical efficacy (e.g., a
delay in tumour progression) now shown to be relevant for non-
cytotoxic agents should also be considered.
Siltuximab was very well tolerated in this study, particularly in
comparison with available therapies. There were no dose- or
schedule-dependent differences in the safety profile. A higher
percentage of patients among the higher-risk patients enrolled in
p a r t2r e p o r t e dS A E s( 2 4 %w i t h3m gk g
–1q3w, 40% with 6mgkg
–1
q3w,) than among the lower-risk patients enrolled in part 3
(15% with 6mgkg
–1q2w). Only one SAE was considered possibly
related to the study agent: cardiac failure in the 6mgkg
–1 q3w
group. Five deaths occurred: two because of PD each in parts 1 and
2 and one because of cerebral haemorrhage secondary to
metastatic disease in part 3. Additionally, no sample obtained
from patients in any part of the study tested positive for immune
response.
Despite the low single-agent activity seen in this study, the
overall study results suggest the potential for further investigation
of siltuximab either at higher doses and/or in combination with
other active agents in the treatment of metastatic RCC.
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Figure 3 Maximal percentage of tumour reduction according to
modified WHO criteria for patients in parts 2 and 3. Dotted lines at
25% and  25% represent the criteria for PD and PR, respectively. Two
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